Excerpts

In the same way, the intensity of TNFA protein expression was highly significant after PAM2 treatment in comparing to sperm and control (P < 0.05) particular in uterine gland of the endometrium compared to the control ( Figure 5B ).

In contrast, collagen type Iα1 and MMP-13 an showed upregulated expression in the M1CM+ TNF-α-group, while the M2CM co-culture group showed a decreasing trend in this regard (all P< 0.05; Figures 3G, H ).

The significant and highly significant differences were set as P < 0.05 and P < 0.01, respectively.

The data were considered significant and highly significant for P -values <0.05 and <0.01, respectively.

The anti-VHSV antibody titer in serum demonstrated an increasing trend from 48 hpiv in the immersion group, which remained significantly ( p < 0.05) higher than that of the NVC control group throughout the immunization period, with further enhancement of the titer at 48 hpc with VHSV.

Of these AABs, three of them—ANGPT2, SELE, and CAV2—are detected in ARDS+ patients with a highly significant difference ( Figure 4A and Figure S4 ) (Wilcoxon test p-value <0.05) over ARDS− patients.

The lowest muscle thickness recorded in the control group was lower than that in all other dietary groups, and the difference was highly significant ( P < 0.05).

A total of 35 proteins exhibited exploratory nominally significant causal associations with UC (IVW p < 0.05).

Meanwhile, studies with higher proportions of patients with AFP > 400 showed a borderline significant trend toward elevated HRs for PFS ( p = 0.05).

In the metastatic disease subgroup, cadonilimab plus chemotherapy ± bevacizumab approached significance for OS (HR = 0.73, 95%CI = 0.52–1.02, p ≈ 0.05) and reached statistical significance for PFS (HR = 0.70, 95%CI = 0.54–0.92, p < 0.05).

After calculating Spearman’s correlation coefficients and correcting for the effect of study center, we identify 30 species and 49 pathways with nominally significant association to the BPDAI score (p < 0.05) ( Figure S3 ).

The overall effect was borderline significant (p = 0.05).

This finding was consistent in sensitivity analysis (SMD ranged from 0.09 to 0.29), although exclusion of the UC subgroup from the Patel study ( 42 ) resulted in a borderline significant difference favoring higher sVCAM-1 levels in the active disease group (SMD 0.29, 95% CI –0.001 to 0.58, p=0.050).

However, E2F2 , ZC3HC1 , RMI1 , JAK2 , EXOC3L1 , and CSF2RB are nominally significant ( P < 0.05), also in the small non-European sample, when adjusting for lead GWAS hits ( Table 3 ).

Levels of sPD-1, sPD-L1, sLAG-3, sICOS, sGITR and sCD86 were significantly higher in mismatch repair deficient tumors (p<0.05, Mann-Whitney U test) and difference in sGITRL was marginally significant (p=0.050, Mann-Whitney U test).

The DeLong test confirmed that the combined model’s AUC was significantly higher than that of HDL ( P = 0.006) and showed a trend toward being higher than SIR max ( P = 0.050).

There was a trend towards the transition period being more stressful for patients who attend at least two other hospital specialists, and for those without any affected family members, but this did not reach statistical significance (fisher exact value 0.0613 in both cases, significant at p <0.05).

As shown in Supplementary Figure S4 , we observed an increasing trend in the risk score in patients with pathological stage IV, and it was higher in the M1 stage compared to the M0 stage (p<0.05), suggesting that the risk score effectively reflects the severity of the disease, particularly in relation to features associated with distant metastasis.

Additionally, the LF-EA group exhibited an increasing trend in spleen index ( P > 0.05), whereas the HF-EA group showed a significant increase in spleen index compared to the LF-EA group ( P < 0.01).

Statistical analysis revealed significantly elevated plasma sICOSL levels in patients with early AE compared to those with early VE, demonstrating a highly significant intergroup difference (P<0.05).

Compared to the model group, the LF-EA group showed a decreasing trend in uterine mass ( P > 0.05), while the HF-EA group demonstrated reductions in uterine mass ( P < 0.05), both the LF-EA group and the HF-EA group showed a trend towards reduced uterine index, transverse diameter of the uterine horns, kidney index, and ovary index ( P > 0.05).

However, anti-EA IgM ( Figure 5D ), and anti-EBNA6 IgM ( Figure 5E ) showed a trend to react differently in ME/CFS samples versus BD control samples ( p > 0.05, Fisher exact test) but did not reach statistical significance.

Non-hematological disorders showed a trend toward a better OS (77.9 vs. 62.9%; p = 0.05).

When we compared the TNFi versus CS monotherapy groups among patients with any tumor type, we found a nearly significant higher risk of all-cause mortality (HR 2.88, 95% CI 1.00-8.35, p=0.05) ( Figure 4A ) and a trend toward a significant higher risk of progression (HR 1.96, 95% CI: 0.94-4.08, p=0.07) ( Figure 4C ).

FEJ treatment showed a trend towards enhancing body weight gain and thymus coefficient and improving the swelling of spleen and liver ( p < 0.05).